https://eccogene.comocreative.com/news/ 2025-10-06T11:34:13+00:00 https://eccogene.comocreative.com/eccogene-raises-cny-180-million-in-series-b-equity-financing-propelling-its-pipeline-of-treatments-for-metabolic-diseases/ 2024-08-25T18:04:07+00:00 https://eccogene.comocreative.com/eccogene-announces-us-ind-approval-for-thr%ce%b2-agonist-ecc4703/ 2024-08-25T18:49:08+00:00 https://eccogene.comocreative.com/eccogene-announces-completed-first-in-human-of-ecc0509-in-phase-1a-clinical-trial-in-australia/ 2024-08-25T18:50:52+00:00 https://eccogene.comocreative.com/eccogene-raised-over-100-million-rmb-financing/ 2024-08-25T18:54:07+00:00 https://eccogene.comocreative.com/eccogene-announced-michael-r-wiley-ph-d-joined-scientific-advisory-board/ 2024-08-25T18:58:00+00:00 https://eccogene.comocreative.com/wp-content/uploads/1608516481186171.png https://eccogene.comocreative.com/eccogene-announces-the-addition-of-jacques-mizrahi-phd-to-scientific-advisory-board/ 2024-08-25T19:03:17+00:00 https://eccogene.comocreative.com/eccogene-announces-us-ind-approval-for-glp-1-receptor-agonist-ecc5004/ 2024-08-26T22:50:33+00:00 https://eccogene.comocreative.com/eccogene-enters-exclusive-license-agreement-with-astrazeneca-to-develop-and-commercialize-small-molecule-glp-1-receptor-agonist-ecc5004-for-cardiometabolic-diseases/ 2024-10-31T17:12:49+00:00 https://eccogene.comocreative.com/eccogene-receives-milestone-payment-of-60-million-from-astrazeneca-following-dosing-of-the-first-patient-in-global-phase-2b-program-of-ecc5004-azd5004-for-the-treatment-of-obesity-and-type-2-diabetes/ 2024-11-14T15:23:55+00:00 https://eccogene.comocreative.com/eccogene-announces-positive-phase-1-data-for-oral-thr-%ce%b2-full-agonist-and-oral-ssao-inhibitor-in-late-breaking-poster-presentations-at-the-american-association-for-the-study-of-liver-diseases-aas/ 2024-11-15T16:50:57+00:00 https://eccogene.comocreative.com/eccogene-announces-formation-of-scientific-advisory-board/ 2025-01-06T19:43:58+00:00 https://eccogene.comocreative.com/eccogene-announces-first-patient-dosed-in-phase-1b-trial-of-azd5004-ecc5004-a-novel-oral-glp-1-receptor-agonist-in-china/ 2025-06-18T11:00:20+00:00 https://eccogene.comocreative.com/eccogene-receives-u-s-fda-clearance-to-initiate-phase-2a-mosaic-trial-of-ecc4703-and-ecc0509-for-mash/ 2025-10-06T11:33:52+00:00 https://eccogene.comocreative.com/eccogene-to-report-preclinical-data-with-ecc4703-showcasing-impact-on-lean-muscle-sparing-and-fat-loss-in-combination-with-semaglutide-and-tirzepatide/ 2025-10-06T11:34:13+00:00